Abstract & Authors:展开
Patients diagnosed with metastatic colorectal cancer (mCRC) often suffer from unresectable metastases, which lead to a rather poor prognosis.1 Although efforts have been made, the need for personalized therapy for mCRC patients is still urgent. Human CRC organoids derived from CRC patients’ primary tumor samples closely recapitulate several properties of the original tumor and provide a platform for personalized therapy design.2,3 However, the dependence of resected primary samples of PDO model limited its application in mCRC patients. Circulating tumor cells (CTCs) are tumor cells that have detached from the primary tumor and circulate in the peripheral blood of patients, which are thought to be critical for cancer metastasis.4 Thus, CTCs have been approved and are used in clinical trials as an important component of liquid biopsies for metastatic breast, prostate, and colorectal cancers.5 It has been reported that CTC organoids were established from patients with advanced prostate cancer,6 providing evidence for the feasibility of culturing organoids from CRC CTCs, and this inspired us to establish a CTC organoid model for future personalized therapy exploration in mCRC patients suffering from unresectable metastases.
Long Zhang,Shaobo Mo,Xiang Hu
Sanjun Cai,Yaqi Li,Junjie Peng
Long Zhang,Shaobo Mo,Xiang Hu,Xiaoji Ma,Weixiang Jin,David Haixiang Peng,Yu Zhou,Xiaofei Liang,Xinxin Rao,Xiaoya Xu,Zhen Zhang,Guoqiang Hua,Sanjun Cai,Yaqi Li,Junjie Peng